Table 2 Baseline clinical characteristics and treatments in PPF and non-PPF groups.

From: Outcomes and prognosis of progressive pulmonary fibrosis in patients with antineutrophil cytoplasmic antibody-positive interstitial lung disease

 

PPF (n = 15)

Non-PPF (n = 23)

Total (n = 38)

 

Age

74.5 ± 8.4

69.8 ± 8.0

71.7 ± 7.8

0.089

Male sex n (%)

11 (73%)

8 (35%)

19 (50%)

0.740

Smoking n (%)

11 (73%)

11 (48%)

22 (58%)

0.258

Smoking index

409.0 ± 514.7

379.1 ± 330.0

390.9 ± 594.0

0.976

MPA-ILD n (%)

6 (40%)

15 (65%)

21 (55%)

0.126

UIP pattern n (%)

7 (47%)

10 (43%)

17 (45%)

0.847

CRP [mg/dL]

2.3 ± 5.6

4.2 ± 6.2

3.4 ± 13.4

0.359

KL-6 [U/mL]

1158.7 ± 1002.3

843.9 ± 704.6

968.1 ± 1743.0

0.425

SP-D [ng/mL]

253.1 ± 227.6

120.2 ± 89.3

182.3 ± 373.4

0.068

MPO-ANCA [U/mL]

55.2 ± 82.7

327.7 ± 683.7

261.4 ± 4.5

0.260

PaO2 [Torr]

84.0 ± 16.0

84.5 ± 10.3

84.3 ± 17.3

0.665

FVC [L]

2.25 ± 0.83

2.58 ± 0.67

2.45 ± 1.86

0.145

%FVC [%]

83.1 ± 22.6

95.0 ± 16.8

90.3 ± 33.4

0.121

%DLCO [%]

68.5 ± 16.0

68.1 ± 17.2

68.3 ± 15.1

0.845

  1. MPA microscopic polyangiitis, ANCA antineutrophil cytoplasmic antibody, IP interstitial pneumonia, HRCT high-resolution computed tomography, UIP usual interstitial pneumonia, CRP C-reactive protein, KL-6 Krebs von den Lungen-6, SP-D surfactant protein D, FVC forced vital capacity, DLCO carbon monoxide diffusing capacity, PPF progressive pulmonary fibrosis, GC glucocorticoid.
  2. *P < 0.05.
Back to article page